securities fraud

Ramaco Resources faces class action securities fraud lawsuit over alleged misrepresentation of Wyoming Brook Mine operations; eligible shareholders must file claims by March 31, 2026.

Law Offices of Howard G. Smith launches securities fraud suits against $VRNS, $CRWV, $BBWI, and Ardent Health. Investors have until March 2026 to file lead plaintiff motions.

Boston Scientific faces securities fraud investigation after 17.6% stock drop triggered by weaker-than-expected electrophysiology division sales in Q4 2025 results.

KDDI faces fraud investigation after ¥246 billion ($1.7B) in fictitious subsidiary revenue discovered. Stock fell 11.4%.

Portnoy Law Firm investigates Apollo Global Management after Financial Times reveals executives, including CEO Marc Rowan, discussed tax arrangements with Jeffrey Epstein in the 2010s, contradicting prior denials.

Class action lawsuit filed against Enphase Energy alleging securities fraud related to undisclosed channel inventory and tax credit impact concerns between April 2025 and October 2025.

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.

Kyndryl Holdings faces securities fraud lawsuit over internal control failures and executive departures. Stock crashed 55% after delayed 10-Q filing disclosure.

Law firm Kahn Swick & Foti files class action against $UGXX over failed Phase 3 trial for rare bone disease drug setrusumab. Investors can apply as lead plaintiffs by April 6.

Kahn Swick & Foti, LLC filed class action lawsuits against Navan, Kyndryl, and Ultragenyx for alleged securities disclosure violations. Lead plaintiff applications due April 24, 2026.

CoreWeave faces class action securities fraud lawsuit alleging overstatement of capacity and understatement of supplier risks between March-December 2025. Lead plaintiff applications due March 13, 2026.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

Ardent Health faces securities fraud lawsuit over alleged failure to disclose collections problems. Stock fell 33% after November revelation of $43M revenue cut and $57.5M EBITDA guidance reduction.

BellRing Brands faces securities fraud lawsuit after 52% stock decline tied to undisclosed inventory issues and weak guidance, with investor deadline March 23, 2026.

Varonis faces class action lawsuit over undisclosed business challenges. Stock crashed 48.7% after disappointing guidance. Investors must act by March 9, 2026.

Varonis faces class action for allegedly misrepresenting ARR growth sustainability, triggering 48.7% stock collapse. Lead plaintiff deadline: March 9, 2026.

KDDI delays earnings amid internal investigation, triggering 11.4% ADR decline and spurring Rosen Law Firm class action lawsuit.

Lufax Holding Ltd ($LU) shares dropped 13.8% on January 27 after announcing auditor removal and potential 2024 annual report delays. Securities investigation launched.

Navan faces class action lawsuit alleging October 2025 IPO documents omitted planned 39% sales-marketing spending increase. Stock down 63% from $25 IPO price to $9.20.

Pomerantz Law Firm investigates Aardvark Therapeutics after Phase 3 trial pause over cardiac safety issues. Stock crashed 56.2% to $5.47.